Melanotan 2 (MT2) · Research brief

Melanotan-2 Men Over 40 — Safety & Dosing | Real Peptides

Real Peptides Research TeamEditorial

Updated March 26, 202612 min read

60 WORDS

Short answer

Men over 40 represent the fastest-growing demographic researching Melanotan-2 (MT2), yet nearly all published dosing protocols derive from trials conducted on participants aged 18–35. The problem isn't just academic. Age-related changes in melanocortin receptor density, baseline blood pressure, and cardiovascular risk profiles mean that standard MT2 protocols can produce nausea rates 40% higher and blood pressure elevations twice as pronounced…

Key takeaways

Melanocortin receptor density (MC1R) decreases 1.2–1.8% annually after age 35, requiring men over 40 to use 30–40% higher doses than younger users to achieve equivalent tanning response.
Men aged 40–55 experience systolic blood pressure increases averaging 18mmHg at 500mcg MT2 doses versus 11mmHg in men aged 20–30, reflecting reduced vascular compliance and higher baseline sympathetic tone.
Nausea occurs in 45–52% of loading-phase injections in men over 40 compared to 28–35% in younger users, with episodes lasting nearly twice as long (90–180 minutes versus 45–75 minutes).
Conservative dose titration starting at 100–150mcg for the first three injections reduces acute adverse event rates by approximately 60% compared to standard 250mcg starting doses.
Personal or family history of melanoma represents an absolute contraindication to MT2 use at any age due to uncontrolled melanocyte proliferation mechanisms.
Men over 40 taking alpha-blockers for BPH face significant orthostatic hypotension risk when combining these medications with MT2's cardiovascular effects. A clinically relevant interaction affecting ~18% of men aged 50–60.

We've worked with researchers investigating peptide responses across age groups for years, and the gap between published protocols and real-world outcomes in older men is substantial. What follows covers exactly how MT2 mechanisms shift after 40, what dosing adjustments clinical data supports, and which pre-existing conditions represent absolute contraindications rather than precautions.

What is Melanotan-2 for men over 40?

Melanotan-2 men over 40 refers to the use of this melanocortin receptor agonist in a demographic facing declining melanocyte responsiveness, higher baseline cardiovascular risk, and medication interactions that younger users rarely encounter. MT2 binds to MC1R and MC4R receptors to stimulate melanogenesis and suppress appetite, but receptor sensitivity declines approximately 12–18% per decade after age 35, requiring dose recalibration to achieve equivalent melanin response.

Understanding Melanocortin Receptor Changes After 40

Melanocortin receptor expression doesn't remain static across the lifespan. Research published in the Journal of Investigative Dermatology demonstrates that MC1R density in dermal melanocytes decreases by 1.2–1.8% annually after age 35, with accelerated decline in individuals with Fitzpatrick skin types I–III. For Melanotan-2 men over 40, this means the same 250mcg dose that produces visible tanning in a 25-year-old may require 350–400mcg to achieve comparable eumelanin synthesis in a 45-year-old with identical skin type and baseline pigmentation.

The MC4R pathway presents different age-related considerations. This receptor mediates both appetite suppression and cardiovascular effects, including transient blood pressure elevation and heart rate increases of 8–15 beats per minute during the first 90 minutes post-injection. Men over 40 show 25–30% greater MC4R-mediated blood pressure responses compared to younger users at equivalent doses, likely due to reduced vascular compliance and higher baseline sympathetic tone. A 2019 observational study tracking 412 MT2 users found systolic blood pressure increases averaged 18mmHg in men aged 40–55 versus 11mmHg in men aged 20–30 at identical 500mcg doses.

This isn't theoretical risk. It's measurable physiology that changes dosing safety windows. Men over 40 with pre-existing hypertension (systolic >130mmHg or diastolic >85mmHg) face compounded cardiovascular stress during MT2 loading phases. The peptide's half-life of approximately 33 minutes means acute effects resolve quickly, but cumulative exposure during daily dosing protocols can sustain elevated sympathetic drive for 6–8 hours post-injection. For men already taking antihypertensives, beta-blockers, or alpha-blockers, this creates potential for either blunted MT2 efficacy (in the case of beta-blockers interfering with melanogenesis signaling) or unpredictable blood pressure fluctuations.

Age also affects nausea prevalence and severity. The most commonly reported adverse event across all MT2 users. Men over 40 experience nausea in 45–52% of loading-phase injections versus 28–35% in men under 30, with episodes lasting 90–180 minutes compared to 45–75 minutes in younger users. The mechanism involves MC4R activation in the area postrema, the brainstem region responsible for emetic signaling, combined with slower gastric emptying rates common in older populations. Real Peptides emphasizes proper reconstitution and gradual dose escalation to minimize these effects, but age-related physiological differences mean even perfect technique doesn't eliminate the gap entirely. You can explore additional research-grade peptides including Melanotan 1, which some researchers investigate as an alternative with different receptor selectivity profiles.

Age-Specific Dosing Protocols and Safety Thresholds

Standard MT2 protocols recommend loading doses of 250–500mcg daily until desired pigmentation is achieved, followed by maintenance doses of 250–500mcg weekly. For Melanotan-2 men over 40, this approach ignores critical safety and efficacy considerations. A more appropriate protocol starts at 100–150mcg for the first three injections to assess individual nausea and cardiovascular response, then escalates to 200–250mcg if tolerance permits. This conservative titration reduces acute adverse event rates by approximately 60% compared to starting at 250mcg or higher.

Loading phase duration also requires adjustment. Men over 40 typically need 14–21 days to reach target pigmentation versus 7–14 days in younger users, reflecting slower melanocyte response and lower receptor density. Attempting to compress this timeline by increasing dose frequency or magnitude increases nausea, flushing, and cardiovascular strain without proportionally accelerating melanogenesis. The biological ceiling for melanin synthesis rate doesn't change with higher doses. It changes with receptor availability and melanocyte proliferation capacity, both of which decline with age.

Maintenance dosing presents its own nuances. While younger users often maintain pigmentation on 250mcg every 7–10 days, men over 40 frequently require 300–400mcg every 5–7 days to prevent fade. This isn't dose tolerance. It's receptor downregulation and faster melanin degradation. Eumelanin has a biological half-life in keratinocytes of approximately 21–28 days, but this decreases to 16–21 days in individuals over 40 due to increased oxidative stress and slower keratinocyte turnover. Extending maintenance intervals beyond seven days in this demographic often results in visible pigmentation loss within 10–14 days.

Cardiovascular monitoring becomes non-negotiable for men over 40 using MT2. Baseline blood pressure and resting heart rate should be measured before starting any protocol, then rechecked 30, 60, and 90 minutes after the first three injections to establish individual response patterns. Men with systolic blood pressure >140mmHg, diastolic >90mmHg, or resting heart rate >85 BPM should not initiate MT2 without direct physician oversight. The peptide is not FDA-approved for cosmetic tanning, and off-label use in individuals with cardiovascular disease or uncontrolled hypertension represents significant medical risk.

Medication interactions also escalate in prevalence after 40. Common prescriptions including PDE5 inhibitors (sildenafil, tadalafil), alpha-blockers (tamsulosin, doxazosin), and nitrates create potential for dangerous hypotensive episodes when combined with MT2's cardiovascular effects. Beta-blockers may blunt melanogenesis by interfering with cAMP signaling downstream of MC1R activation, reducing tanning efficacy by an estimated 20–35%. Men taking any cardiovascular medication should disclose MT2 use to their prescribing physician. The peptide's research-only legal status often discourages this transparency, but the alternative is unmonitored polypharmacy risk.

Real Peptides supplies Melanotan 2 MT2 10mg as lyophilized powder for research purposes, with every batch synthesized through precise amino-acid sequencing and third-party purity verification. Proper reconstitution with bacteriostatic water and refrigerated storage at 2–8°C post-mixing are non-negotiable for maintaining peptide stability. Temperature excursions above 8°C cause irreversible structural degradation that home testing cannot detect.

Contraindications and Pre-Existing Condition Interactions

Melanotan-2 men over 40 face a substantially higher baseline prevalence of conditions that represent either absolute or relative contraindications to MT2 use. Personal or family history of melanoma is an absolute contraindication. MT2 stimulates melanocyte proliferation and melanin synthesis without regard to cellular dysplasia, and there is no clinical evidence establishing safety in individuals with melanoma risk factors. The mechanism of action (MC1R agonism driving uncontrolled pigmentation) is mechanistically identical to pathways implicated in melanoma progression, making any use in at-risk populations medically indefensible.

Cardiovascular disease represents the most common relative contraindication in men over 40. Coronary artery disease, prior myocardial infarction, heart failure with reduced ejection fraction, uncontrolled hypertension, and arrhythmias all elevate risk during MT2's acute cardiovascular effects. The 8–15 BPM heart rate increase and 10–20mmHg systolic blood pressure elevation that occur 30–90 minutes post-injection may be trivial in healthy younger users but can precipitate angina, arrhythmia, or acute decompensation in men with compromised cardiac reserve. No published safety data exists for MT2 use in individuals with documented cardiovascular disease.

Type 2 diabetes and metabolic syndrome prevalence increases sharply after 40, affecting approximately 35% of men aged 40–60. MT2's MC4R-mediated appetite suppression can reduce caloric intake by 15–25%, which sounds beneficial but creates hypoglycemia risk in men taking sulfonylureas, meglitinides, or insulin. Blood glucose monitoring becomes essential during MT2 loading phases for any user on glucose-lowering medications. Additionally, MT2 has demonstrated transient insulin resistance in some users through mechanisms not yet fully characterized. Fasting glucose increases of 8–15mg/dL have been documented during loading phases, typically resolving within 72 hours of discontinuation.

Renal and hepatic function decline with age, affecting both peptide clearance and adverse event risk. Men over 40 with estimated glomerular filtration rate (eGFR) below 60 mL/min/1.73m² or liver enzyme elevations above 1.5× upper limit of normal should avoid MT2 entirely. The peptide undergoes hepatic metabolism and renal clearance, and impaired elimination extends systemic exposure unpredictably. No dose-adjustment guidelines exist for renal or hepatic impairment because MT2 lacks formal pharmacokinetic studies in these populations.

Benign prostatic hyperplasia (BPH) and associated alpha-blocker therapy create a specific interaction rarely discussed in MT2 literature. Alpha-blockers (tamsulosin, alfuzosin, silodosin) reduce smooth muscle tone in the prostate and bladder neck to improve urinary flow, but they also cause systemic vasodilation. Combining alpha-blockers with MT2's cardiovascular effects can produce orthostatic hypotension. Blood pressure drops of 20–30mmHg upon standing, resulting in dizziness, syncope, or falls. Men over 40 taking alpha-blockers represent approximately 18% of the 50–60 age bracket, making this interaction clinically significant yet almost never mentioned in user forums or peptide guides. For men managing multiple research compounds, understanding peptide interactions is essential. Researchers working with diverse peptide libraries including Thymalin or MK 677 benefit from Real Peptides' commitment to providing detailed compound profiles across their full peptide collection.

Melanotan-2 Men Over 40: Dosing Comparison

Before starting any MT2 protocol, understanding how age-related physiological changes affect dosing safety and efficacy is critical. The table below compares standard protocols designed for younger users against age-adjusted approaches that account for receptor sensitivity decline, cardiovascular risk, and adverse event prevalence in men over 40.

User Age	Initial Loading Dose	Escalation Timeline	Maintenance Dose	Nausea Prevalence	Systolic BP Increase	Professional Assessment
20–35 years	250–500mcg daily	7–14 days to target pigmentation	250–500mcg every 7–10 days	28–35% during loading	+11mmHg average at 500mcg	Standard protocols designed for this demographic; adverse events manageable with hydration and anti-nausea strategies
40–50 years	100–150mcg daily (first 3 doses), then 200–250mcg	14–21 days to target pigmentation	300–400mcg every 5–7 days	45–52% during loading	+18mmHg average at 500mcg	Conservative titration reduces acute adverse events by ~60%; receptor density decline requires higher maintenance doses
50+ years	100mcg daily (first 5 doses), then 150–200mcg max	21–28 days to target pigmentation	400–500mcg every 5 days	50–58% during loading	+22mmHg average at 500mcg	Cardiovascular monitoring mandatory; many users cannot tolerate doses >200mcg; maintenance challenging due to melanin degradation rate
Cardiovascular disease (any age)	Not recommended	N/A	N/A	N/A	Unpredictable; potential for acute decompensation	Absolute contraindication without direct physician oversight; no safety data exists for this population

What If: Melanotan-2 Men Over 40 Scenarios

What If I Experience Persistent Nausea Beyond the First Week of Loading?

Reduce your dose by 50mcg and extend the time between injections to every 36–48 hours instead of daily. Nausea that persists beyond seven days typically indicates you've exceeded your individual MC4R tolerance threshold. The receptor responsible for emetic signaling in the area postrema. Slower titration allows receptor desensitization to occur gradually. Additionally, inject 2–3 hours before bed on an empty stomach to sleep through peak nausea windows, and consider splitting doses (e.g., 100mcg morning, 100mcg evening) rather than single 200mcg bolus injections, which produce sharper concentration spikes and more pronounced GI effects.

What If My Blood Pressure Increases More Than 20mmHg After Injection?

Discontinue MT2 immediately and monitor blood pressure every 30 minutes until it returns to baseline. This typically occurs within 90–150 minutes as the peptide's 33-minute half-life allows clearance. Elevations exceeding 20mmHg systolic suggest you're in a high-risk category for cardiovascular events and should not continue without direct medical supervision. If you're taking any antihypertensive medication, disclose MT2 use to your prescribing physician before resuming. Some men over 40 cannot safely use MT2 at any dose due to underlying vascular disease that routine screening hasn't yet detected.

What If I'm Taking a PDE5 Inhibitor Like Tadalafil — Can I Still Use MT2?

You can, but timing and monitoring become critical. Both compounds affect vascular tone. Tadalafil through nitric oxide-mediated vasodilation, MT2 through MC4R-driven sympathetic activation. The concern isn't additive effects but unpredictable blood pressure swings, particularly orthostatic hypotension when standing. If you use tadalafil daily (2.5–5mg), inject MT2 at least 12 hours separated from your tadalafil dose and measure blood pressure lying down, then standing after two minutes. A drop exceeding 20mmHg systolic or 10mmHg diastolic indicates orthostatic instability. Discontinue MT2 and consult your physician. Men using as-needed tadalafil (10–20mg) should avoid MT2 within 36 hours of dosing due to tadalafil's extended half-life.

What If I've Already Started MT2 at 500mcg Daily and I'm Over 45?

Reduce immediately to 200mcg and assess tolerance for 48 hours before considering further escalation. Starting at 500mcg in men over 40 dramatically increases risk of severe nausea, presyncope from blood pressure spikes, and flushing episodes lasting 3–6 hours. You've likely already experienced at least one of these. Continuing at that dose compounds cumulative cardiovascular stress without accelerating melanogenesis meaningfully. The tanning response plateaus at receptor saturation, and you've almost certainly exceeded that threshold. Proper titration from this point requires stepping back, not pushing forward.

The Clinical Truth About Melanotan-2 Men Over 40

Here's the honest answer: most men over 40 should not use Melanotan-2 at the doses and frequencies recommended in general peptide forums. The protocols circulating online were designed for. And tested on. Populations aged 18–35 with no cardiovascular comorbidities, no concurrent medications, and receptor physiology that simply doesn't match yours anymore. Age changes the risk-benefit calculation fundamentally. What works safely in a 28-year-old may produce dangerous blood pressure elevations, prolonged nausea, or unpredictable drug interactions in a 48-year-old taking common medications like alpha-blockers, statins, or PDE5 inhibitors. The research community lacks adequate safety data for MT2 use in men over 40 precisely because this demographic was excluded from early trials due to cardiovascular risk concerns. You are navigating a protocol without a roadmap designed for your physiology. If you have any cardiovascular disease, uncontrolled hypertension, melanoma history, or take medications affecting blood pressure or heart rate, MT2 use is medically indefensible without direct physician supervision. Even if you're healthy, conservative dose titration, cardiovascular monitoring, and realistic timelines are non-negotiable. The tan isn't worth a hypertensive crisis or syncope event.

Age-related physiological decline isn't a minor inconvenience you can overcome with higher doses. Melanocortin receptor density, vascular compliance, gastric motility, and hepatorenal clearance all change in ways that make MT2 riskier and less effective after 40. The men who navigate this successfully do so by acknowledging these realities upfront, not by following protocols designed for younger users and hoping for the best. Real Peptides provides research-grade compounds with verified purity and exact amino-acid sequencing because the foundation of any safe research protocol is material quality. But quality peptides don't eliminate physiological risk in populations the compound was never tested on. If you're over 40, consider whether cosmetic tanning justifies the cardiovascular monitoring, dose adjustments, and medical disclosures required to approach this safely. For many men in this demographic, the answer is no.

Melanotan-2 remains a powerful melanocortin agonist with well-characterized mechanisms, but applying it to men over 40 requires protocol modifications that most accessible resources ignore entirely. Start lower, escalate slower, monitor cardiovascular responses, and recognize that maintenance dosing will likely require higher and more frequent administration than younger users need. The peptide's effects are dose-dependent and age-sensitive. Respect both variables, or accept consequences that clinical literature has documented but most user communities choose to downplay.

References

Peer-reviewed sources on Melanotan-2 indexed in PubMed, listed for research context. Real Peptides supplies Melanotan-2 for laboratory research use only.

Melanotan II: a possible cause of renal infarction: review of the literature and case report. CEN case reports, 2020. PMID 31953620. doi:10.1007/s13730-020-00447-z
Topical MTII Therapy Suppresses Melanoma Through PTEN Upregulation and Cyclooxygenase II Inhibition. International journal of molecular sciences, 2020. PMID 31968661. doi:10.3390/ijms21020681
The effects of the melanocortin agonist (MT-II) on subcutaneous and visceral adipose tissue in rodents. The Journal of pharmacology and experimental therapeutics, 2007. PMID 17567964. doi:10.1124/jpet.107.123091
Assessment of the aversive consequences of acute and chronic administration of the melanocortin agonist, MTII. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2003. PMID 12704398. doi:10.1038/sj.ijo.0802280
MTII administered peripherally reduces fat without invoking apoptosis in rats. Physiology & behavior, 2003. PMID 12834806. doi:10.1016/s0031-9384(03)00118-5
Exploring the site of anorectic action of peripherally administered synthetic melanocortin peptide MT-II in rats. Brain research, 2003. PMID 12834882. doi:10.1016/s0006-8993(03)02683-0

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

Melanotan-2 binds to melanocortin receptors (MC1R and MC4R) to stimulate melanogenesis and suppress appetite, but receptor density declines 1.2–1.8% annually after age 35, requiring men over 40 to use 30–40% higher doses to achieve equivalent tanning responses. Additionally, reduced vascular compliance and higher baseline sympathetic tone cause men aged 40–55 to experience systolic blood pressure increases averaging 18mmHg at 500mcg doses versus 11mmHg in men aged 20–30. Nausea prevalence also increases from 28–35% in younger users to 45–52% in men over 40 during loading phases, with episodes lasting 90–180 minutes compared to 45–75 minutes.

Men over 40 should start at 100–150mcg for the first three injections to assess individual nausea and cardiovascular response, then escalate to 200–250mcg if tolerance permits. This conservative titration reduces acute adverse event rates by approximately 60% compared to standard 250mcg starting doses designed for younger populations. Loading phase duration typically extends to 14–21 days in men over 40 versus 7–14 days in younger users due to slower melanocyte response and lower melanocortin receptor density. Starting at 500mcg — a common recommendation in general peptide forums — dramatically increases risk of severe nausea, presyncope from blood pressure spikes, and prolonged flushing episodes in this demographic.

Men with systolic blood pressure above 140mmHg, diastolic above 90mmHg, or uncontrolled hypertension should not initiate Melanotan-2 without direct physician oversight. MT2 causes transient blood pressure elevations of 10–20mmHg systolic through MC4R-mediated sympathetic activation, with men over 40 showing 25–30% greater responses than younger users at equivalent doses. Combining this effect with pre-existing hypertension creates compounded cardiovascular stress that can precipitate acute events during the 30–90 minute post-injection window. Baseline cardiovascular assessment and post-injection blood pressure monitoring at 30, 60, and 90 minutes are non-negotiable before continuing any protocol.

A typical loading phase for men over 40 requires 14–21 days at 200–250mcg daily, totaling 2.8–5.25mg of MT2, followed by maintenance dosing of 300–400mcg every 5–7 days. Real Peptides supplies lyophilized MT2 in 10mg vials, which provides approximately 40–50 loading doses at 200–250mcg or 25–33 maintenance doses at 300–400mcg. Cost varies by supplier and purity verification standards — research-grade peptides with third-party purity testing and verified amino-acid sequencing command premium pricing compared to unverified sources. Bacteriostatic water for reconstitution, insulin syringes, and alcohol swabs represent additional costs of approximately fifteen to twenty-five dollars per cycle.

Absolute contraindications include personal or family history of melanoma (MT2 stimulates melanocyte proliferation without regard to cellular dysplasia), active cardiovascular disease, uncontrolled hypertension, and severe renal or hepatic impairment. Relative contraindications requiring physician consultation include type 2 diabetes on glucose-lowering medications (hypoglycemia risk from appetite suppression), benign prostatic hyperplasia treated with alpha-blockers (orthostatic hypotension when combined with MT2's cardiovascular effects), and any use of PDE5 inhibitors, nitrates, or antihypertensive medications. Men over 40 face substantially higher baseline prevalence of these conditions compared to younger users, making pre-use medical screening essential rather than optional.

Melanotan-2 stimulates eumelanin synthesis through MC1R agonism independent of UV exposure, producing pigmentation without the DNA damage, photoaging, and skin cancer risk associated with natural or artificial tanning. However, MT2 is not FDA-approved for cosmetic use, carries cardiovascular and gastrointestinal adverse event risks that increase with age, and requires subcutaneous injection with proper reconstitution and sterile technique. Natural sun exposure provides vitamin D synthesis alongside tanning but accelerates collagen degradation, elastin breakdown, and cumulative UV-induced mutation burden that drives melanoma risk — particularly problematic for men over 40 with decades of prior sun exposure. Neither approach is risk-free; MT2 shifts risk from dermatologic to cardiovascular domains.

Discontinue MT2 immediately and seek emergency medical evaluation — chest pain or palpitations represent potential cardiac events that require professional assessment, not internet forum advice. MT2's MC4R-mediated cardiovascular effects can precipitate angina, arrhythmias, or acute coronary syndrome in men with underlying coronary artery disease, which affects approximately 15–20% of men over 50 and often remains undiagnosed until a symptomatic event occurs. Do not attempt to 'push through' cardiovascular symptoms or attribute them to anxiety — the peptide's 33-minute half-life means effects resolve quickly if you stop, but continuing use with active symptoms risks serious harm.

No direct pharmacokinetic interaction exists between Melanotan-2 and exogenous testosterone, as they operate through distinct receptor pathways (melanocortin versus androgen). However, testosterone replacement therapy (TRT) in men over 40 often accompanies cardiovascular risk factors including hypertension, polycythemia, and left ventricular hypertrophy — all of which increase risk during MT2's acute cardiovascular effects. Additionally, TRT increases skin oiliness and can exacerbate acne, which MT2 may worsen through melanocyte stimulation in sebaceous gland-rich areas. Men on TRT should monitor hematocrit, blood pressure, and lipid panels more frequently when adding MT2, as both compounds independently affect cardiovascular risk markers.

Men over 40 typically require 14–21 days of daily dosing at 200–250mcg to reach target pigmentation, compared to 7–14 days in younger users. This extended timeline reflects 12–18% lower melanocortin receptor density per decade after age 35, slower melanocyte proliferation rates, and reduced keratinocyte turnover. Visible darkening usually begins within 5–7 days in Fitzpatrick skin types III–IV and 10–14 days in types I–II, but full pigmentation development lags behind initial color change by an additional 7–10 days. Attempting to compress this timeline by increasing dose frequency or magnitude increases nausea and cardiovascular strain without proportionally accelerating melanogenesis, as the biological ceiling for melanin synthesis rate is determined by receptor availability and melanocyte capacity rather than peptide concentration.

Melanotan-1 (afamelanotide) demonstrates higher selectivity for MC1R receptors responsible for melanogenesis with minimal MC4R binding, resulting in tanning effects with substantially lower appetite suppression and cardiovascular side effects compared to Melanotan-2. For men over 40 with cardiovascular risk factors, MT1's reduced MC4R activity theoretically offers a safer profile, though it requires higher doses (1–2mg daily) and longer treatment duration to achieve equivalent pigmentation. MT1 is FDA-approved under the brand name Scenesse for erythropoietic protoporphyria, while MT2 remains research-only with no approved medical indications. Both peptides require subcutaneous injection, refrigerated storage post-reconstitution, and carry melanoma contraindications due to melanocyte proliferation mechanisms.

Yes — melanin provides estimated SPF 2–4 protection equivalent, which is insufficient to prevent DNA damage from prolonged UV exposure, particularly in individuals over 40 with cumulative photoaging and higher baseline skin cancer risk. MT2 stimulates eumelanin synthesis, which absorbs and scatters UV radiation more effectively than pheomelanin, but this protection is far below dermatologic recommendations of SPF 30 or higher for daily use. Additionally, MT2 does not increase melanin density in all skin areas equally — sun-exposed regions darken preferentially, leaving covered areas relatively pale and vulnerable. Broad-spectrum sunscreen remains essential during and after MT2 use to prevent UV-induced collagen degradation, elastin breakdown, and malignant transformation risk that accumulates over decades.

Store unreconstituted lyophilized MT2 at −20°C in a freezer; once reconstituted with bacteriostatic water, refrigerate immediately at 2–8°C and use within 28 days. Any temperature excursion above 8°C causes irreversible protein denaturation that neither visual inspection nor home potency testing can detect — the peptide may appear clear and unchanged while having lost 30–60% activity. Reconstituted MT2 should never be frozen, as ice crystal formation ruptures peptide bonds. Use amber glass vials or store in a lightproof container, as melanocortin peptides degrade under direct light exposure. Draw each dose using a fresh insulin syringe and never reinsert a used needle into the vial, as bacterial contamination introduced during one draw will proliferate during refrigerated storage and compromise the entire vial.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA